This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignee: Pacific Edge Limited. Active years: 2019-2020.
Location History:
- Dunedin, NZ (2019)
- Christchurch, NZ (2020)
Company Filing History:
Years Active: 2019-2020
Title: Andrew John Holyoake: Innovator in Gastric Cancer Detection
Introduction
Andrew John Holyoake is a notable inventor based in Christchurch, New Zealand. He has made significant contributions to the field of cancer detection, particularly focusing on gastric cancer. With a total of 2 patents, Holyoake's work is pivotal in improving early detection methods for this serious illness.
Latest Patents
Holyoake's latest patents include innovative methods for the treatment of recurrent gastric cancer identified using genetic biomarkers. Early detection of tumors is a major determinant of survival for patients suffering from gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor types, making them valuable markers for cancer detection. GTM proteins can be released from cancer cells and can reach sufficiently high concentrations in serum and other fluids, allowing for their detection. Thus, methods and test kits for the detection and quantification of GTM provide a valuable tool for diagnosing gastric cancer.
Career Highlights
Holyoake is associated with Pacific Edge Limited, a company dedicated to advancing cancer diagnostics. His work at this organization has been instrumental in developing innovative solutions for cancer detection and treatment.
Collaborations
Holyoake collaborates with Parry John Guilford, a fellow innovator in the field. Their combined expertise enhances the research and development efforts at Pacific Edge Limited.
Conclusion
Andrew John Holyoake's contributions to the field of gastric cancer detection are significant and impactful. His innovative patents and collaborations continue to advance the understanding and diagnosis of this critical health issue.